Mint-betahistine 8, 16 & 24mg: Data Integrity Concerns With Product's Bioequivalence Data That Could Lead To Incorrect Dosing.

Mint-Betahistine tablets in 8mg, 16mg, and 24mg strengths are being recalled across Canada due to data integrity issues with the product's bioequivalence testing. These problems mean the medication may not deliver the correct dose as intended. The recall affects all Mint-Betahistine products distributed in Canada.

Product

Mint-Betahistine 8, 16 & 24mg

Reason

Product quality

Classification

Class I

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2024-06-06

Status

Ongoing

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/e08c1ded-5638-4f8f-a8fb-6da9a7d2c8eb